CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 93 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q2 2020. The put-call ratio across all filers is 0.10 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $12,842,000 | +53.0% | 108,451 | +52.6% | 0.00% | 0.0% |
| Q4 2020 | $8,392,000 | +20.9% | 71,052 | +13.8% | 0.00% | – |
| Q3 2020 | $6,942,000 | +12.3% | 62,459 | +3.2% | 0.00% | – |
| Q2 2020 | $6,183,000 | +3.8% | 60,514 | +9.6% | 0.00% | -100.0% |
| Q1 2020 | $5,959,000 | -11.1% | 55,212 | -4.1% | 0.00% | – |
| Q4 2019 | $6,700,000 | +8.4% | 57,566 | +6.6% | 0.00% | – |
| Q3 2019 | $6,182,000 | +85.5% | 54,006 | +54.4% | 0.00% | – |
| Q2 2019 | $3,333,000 | -1.2% | 34,977 | -5.3% | 0.00% | – |
| Q1 2019 | $3,372,000 | +62.1% | 36,953 | +34.9% | 0.00% | – |
| Q4 2018 | $2,080,000 | -0.6% | 27,397 | +4.8% | 0.00% | – |
| Q3 2018 | $2,092,000 | +5.0% | 26,149 | +30.3% | 0.00% | – |
| Q2 2018 | $1,993,000 | +23.2% | 20,070 | +0.5% | 0.00% | – |
| Q1 2018 | $1,618,000 | +32.5% | 19,968 | +28.9% | 0.00% | – |
| Q4 2017 | $1,221,000 | -5.6% | 15,493 | +10.5% | 0.00% | – |
| Q3 2017 | $1,293,000 | – | 14,024 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Maso Capital Partners Ltd | 143,300 | $11,464,000 | 11.16% |
| Hillhouse Capital Management | 2,751,200 | $220,096,000 | 5.88% |
| York Capital Management Global Advisors, LLC | 1,167,643 | $93,411,000 | 2.95% |
| Kite Lake Capital Management (UK) LLP | 152,836 | $12,227,000 | 2.53% |
| RUDMAN ERROL M | 80,000 | $6,400,000 | 2.39% |
| Dalton Investments, Inc. | 54,551 | $4,364,000 | 2.04% |
| Greenwoods Asset Management Ltd | 245,000 | $19,600,000 | 1.91% |
| Point72 Hong Kong Ltd | 47,296 | $3,784,000 | 1.29% |
| Temasek Holdings (Private) Ltd | 990,000 | $79,200,000 | 0.46% |
| Kassirer Asset Management Corp | 6,000 | $480,000 | 0.32% |